Advanz-full-RGB (002).jpg
ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe
05 sept. 2024 02h35 HE | Advanz Pharma
ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The European Commission’s decision to revoke the OCALIVA®...
Advanz-full-RGB (002).jpg
ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC)
03 sept. 2024 04h00 HE | Advanz Pharma
ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) OCALIVA® is the only farnesoid X...